Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
RESEARCH TOOLSreports
Holding TEVA?
Track your performance easily
Earnings Data
Report Date
Jan 29, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.7Last Year’s EPS
1Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2018
|% Change Since: -13.89%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment due to strong revenue growth, robust performance in innovative and generics segments, and improved financial metrics. Despite some challenges such as legal settlements and an operating loss, Teva's strategic execution and positive credit rating outlook suggest strong future potential.Company Guidance
During the Q3 2024 earnings call, Teva Pharmaceuticals provided an optimistic financial outlook driven by a consistent 15% revenue growth, reaching $4.3 billion, alongside an adjusted EBITDA of $1.3 billion, up 17%. The company highlighted strong performance from its innovative drugs AUSTEDO, AJOVY, and UZEDY, with growth rates of 28%, 21%, and anticipated full-year revenue of $100 million for UZEDY, respectively. Additionally, Teva's global generics business saw a 17% increase, with significant contributions from recent launches such as generic Revlimid and Victoza. The company reported a strong free cash flow of $922 million and noted its focus on debt repayment with a net debt to EBITDA ratio of three. As a result of these strong performances, Teva raised its 2024 full-year revenue guidance to $16.1 billion to $16.5 billion and EPS guidance to $2.40 to $2.50.Strong Revenue Growth
Revenues for Q3 2024 were $4.3 billion, an increase of 15% in local currency terms compared to the third quarter of 2023.
Innovative Portfolio Performance
AUSTEDO grew by 28%, AJOVY by 21%, and UZEDY had a strong performance, prompting an increase in full-year guidance from $80 million to $100 million.
Generics and TAPI Growth
Global generics business grew by 17%, with 30% in the US. TAPI business recorded its third consecutive quarter of growth at 4%.
Improved Financial Metrics
Adjusted EBITDA was $1.3 billion, up 17%, and EPS increased by 16%.
Positive Credit Ratings
Credit ratings agencies have upgraded Teva's outlook, with Fitch upgrading Teva’s rating to BB, the first upgrade in over a decade.
---
TEVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TEVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 29, 2025 | $21.53 | $18.54 | -13.89% |
| Nov 06, 2024 | $18.77 | $17.43 | -7.14% |
| Jul 31, 2024 | $16.41 | $17.43 | +6.22% |
| May 08, 2024 | $13.95 | $15.74 | +12.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Teva Pharmaceutical (TEVA) report earnings?
Teva Pharmaceutical (TEVA) is schdueled to report earning on Jan 29, 2025, TBA Not Confirmed.
What is Teva Pharmaceutical (TEVA) earnings time?
Teva Pharmaceutical (TEVA) earnings time is at Jan 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TEVA EPS forecast?
TEVA EPS forecast for the fiscal quarter 2024 (Q4) is 0.7.
---
